GSK

Bittium Wearable Platform with Philips EmoGraphy & CardioSense Solution Was Awarded in the GSK’s “Transform the Future of Self-Care” Innovation Contest

Biotech and pharma companies tap new members of executive leadership teams and boards.

According to a report, GSK has bundled the products into three separate packets in order to attract regional buyers.

The trial found that Sci-B-Vac was non-inferior to Engerix-B, two of its primary endpoints, but it did not reach the secondary endpoint.

The Laboratory for Genomics Research will be funded by GSK up to $67 million over the five-year period and will include space for 24 full-time university employees and up to 14 full-time GSK staffers.

A Phase III trial compared Sanofi’s Soliqua/Suliqua to other GLP-1 receptor agonists (GLP-1 RA), with Soliqua showing a superior decrease of average blood sugar level (HbA1c) after 26 weeks.

Yukin Therapeutics, a French company specializing in the development of new molecules for cancer treatment, has completed a €3.3 million financing round for the development and optimization of its proprietary therapeutic molecules.

Orchard Therapeutics, Fondazione Telethon and Ospedale San Raffaele announced that Orchard has been granted an exclusive worldwide license to intellectual property rights to research, develop, manufacture and commercialize the ex vivo autologous hematopoietic stem cell (HSC) gene therapy program for the treatment of Mucopolysaccharidosis Type I (MPS-I) developed by the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.

Orchard sees the gene therapy acquired as a potential treatment to “fundamentally change the lives of patients” who are born with this debilitating condition.